Long-term safety study of CB03-154 for epilepsy
Part of Brain & nervous system clinical trials.
This study is a long-term follow-up for people with epilepsy who already completed a previous trial of the drug CB03-154. It checks if the drug remains safe and effective over more time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have completed the previous CB03-154-EP201 study without quitting early.
- You did not have any serious side effects or problems that would prevent you from continuing.
- The study doctor must agree that it is safe for you to participate and that you can follow the study rules.
- You must be able to keep a daily record of your seizures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication, CB03-154, to see if it is safe and can reduce seizures in adults with focal epilepsy. You may be able to join if you have had focal epilepsy for at least 2 years and are on a stable dose of 1 to 3 anti-seizure medications.
This study checks the long-term safety of BHV-7000 for people who already completed an earlier trial with this drug. You keep taking the same medicine while doctors watch for any side effects over time.
This study gives XEN1101 in an open-label way (everyone knows they’re getting the drug) to people who finished earlier epilepsy studies. It aims to see how the treatment continues to work and whether it’s safe over the long term.
This study tests a new medicine called BHV-7000 for adults whose focal seizures (starting in one part of the brain) are not controlled by current treatments. The goal is to see if it can reduce seizures safely.
This study tests the long-term safety and effectiveness of RAP-219, an investigative medication for focal epilepsy. It is for people who already completed an earlier study of RAP-219, have a type of epilepsy that doesn't respond to standard medicines, and use a surgically implanted brain device (RNS system) to help manage seizures.
This trial tests XEN1101 compared with a placebo (inactive pill) in people with focal-onset seizures that haven’t been fully controlled despite trying at least two anti-seizure medicines. If you qualify, you may help researchers see whether the study drug reduces seizure frequency and improves control.
Hear when a new Focal Epilepsy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.